2408131-71-3
2408131-71-3
Chemical Structure
Bempedoic acid-d5
Synonym(s): ETC-1002-d5;ESP-55016-d5
- CAS. Nr.: 2408131-71-3
- Formula:C19H31D5O5
- Molecular Weight:349.52
IUPAC Name: 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic-7,7,8,9,9-d5 acid
InChIKey: HYHMLYSLQUKXKP-ALWHKASXSA-N
SMILES: OC(C(C)(C)CCCCC([2H])([2H])C(O)([2H])C([2H])([2H])CCCCC(C)(C)C(O)=O)=O
Biological Activity: Bempedoic acid-d5 is the deuterium labeled Bempedoic acid[1]. Bempedoic acid (ETC-1002) is an ATP-citrate lyase (ACL) inhibitor[1]. Bempedoic acid (ETC-1002) activates AMPK[2].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Bempedoic acid-d5 | Bempedoic acid-d5 is the deuterium labeled Bempedoic acid. Bempedoic acid (ETC-1002) is an ATP-citrate lyase (ACL) inhibitor. Bempedoic acid (ETC-1002) activates AMPK. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Bempedoic acid (Standard) | ≥98% | Bempedoic acid (Standard) is the analytical standard of Bempedoic acid. This product is intended for research and analytical applications. Bempedoic acid (ETC-1002) is an ATP-citrate lyase (ACL) inhibitor. Bempedoic acid (ETC-1002) activates AMPK. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Bempedoic acid-d4 | 98.0% | Bempedoic acid-d4 is the deuterium labeled Bempedoic acid. Bempedoic acid (ETC-1002) is an ATP-citrate lyase (ACL) inhibitor. Bempedoic acid (ETC-1002) activates AMPK. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Bempedoic acid | 99.88% | Bempedoic acid (ETC-1002) is an ATP-citrate lyase (ACL) inhibitor. Bempedoic acid (ETC-1002) activates AMPK. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
- [2]. Pinkosky SL, et al. AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. J Lipid Res. 2013 Jan;54(1):134-51. [Content Brief]
